Clinical trials: Pseudomonas Aeruginosa Infection
Bronchiectasis Adult, Pseudomonas Aeruginosa Infection
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can become chronic and lead to increased death rates and disease severity.
- Trial name
- ERASE (NCT06093191)
- Testing
- Tobramycin Inhalant Product, Ciprofloxacin 750 MG, Natural saline inhalation
- Where
- 60 sites in China
- Volunteers
- 371 people
- Sponsor
- Jin-Fu Xu
Infections, Infection, Bacterial
Development and Validation of (Bio)Sensors for the Identification of Pathogens
The recent COVID-19 pandemic has revealed the need to develop tests that are accurate, rapid, and inexpensive for the diagnosis of infectious diseases.
- Conditions
- Infections, Infection, Bacterial, Infection Viral, Infection, Parasite
- Trial name
- NCT06548841
- Testing
- Nanobiotechnology platforms
- Where
- Italy
- Volunteers
- 149 people
- Sponsor
- University of Bologna
Pseudomonas Infections, Pseudomonas Septicemia
Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in…
- Conditions
- Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia, Pseudomonal Bacteraemia
- Trial name
- MIPSA (NCT03044223)
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Ulm
Pseudomonas Aeruginosa, Colonization, Asymptomatic
Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Pseudomonas aeruginosa causes severe infections in hospitalized patients. The worldwide emergence of carbapenem-resistant P. aeruginosa (CRPA) makes infections by these pathogens almost untreatable.
- Conditions
- Pseudomonas Aeruginosa, Colonization, Asymptomatic, Nosocomial Infection
- Trial name
- SAMPAN (NCT05282082)
- Where
- 3 sites in Indonesia, Italy and 1 more
- Volunteers
- 2,105 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic…
- Conditions
- Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
- Trial name
- Tailwind (NCT05616221)
- Testing
- AP-PA02
- Where
- 23 sites in United States
- Volunteers
- 48 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection, Severe Infection, Pseudomonas Aeruginosa
- Trial name
- OPTIMISE (NCT05210387)
- Testing
- Duration of therapy
- Where
- 29 sites in Brazil
- Volunteers
- 107 people
- Sponsor
- Hospital Moinhos de Vento
Healthy
Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
The objective is to confirm the optimal dose of IC43 in regard to immunogenicity, safety and tolerability.
- Trial name
- NCT00778388
- Testing
- IC43
- Where
- 3 sites in Austria, Germany
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Cystic Fibrosis, Infection
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo
Our data indicate that the CFTR-molecule functions as a transporter for sphingosine-1-phosphate and sphingosine or regulates the uptake of these sphingolipids by epithelial cells.
- Conditions
- Cystic Fibrosis, Infection, Pseudomonas Aeruginosa
- Trial name
- NCT00515229
- Testing
- amitriptyline
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- University Hospital Tuebingen
Cystic Fibrosis
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF1 (NCT00112359)
- Testing
- AZLI 75 mg three times a day (TID)
- Where
- 53 sites in United States, Australia and 2 more
- Volunteers
- 166 people
- Sponsor
- Gilead Sciences
Bronchiectasis Adult
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
The ERASE II study is a prospective follow-up study designed to assess the long-term impact of successful eradication of Pseudomonas aeruginosa (PA) in patients with bronchiectasis.
- Trial name
- NCT06760273
- Testing
- No Intervention: Observational Cohort
- Where
- 58 sites in China
- Volunteers
- 364 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Cystic Fibrosis
Evaluation of the Emission Distance of P. Aeruginosa From the Respiratory Tract of People With Cystic Fibrosis
It is well known that an association exists between the acquisition of some respiratory pathogens and prognosis of CF people. About 57 % of patients has a lung infection due to P.aeruginosa (PA).
- Trial name
- NCT00531531
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- University of Florence
Persistent Infection, Cystic Fibrosis
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.
- Trial name
- NCT06159725
- Testing
- CMTX-101
- Where
- 23 sites in United States
- Volunteers
- 43 people
- Sponsor
- Clarametyx Biosciences, Inc.
Pressure Ulcer
Phage Therapy for the Prevention and Treatment of Pressure Ulcers.
This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aeruginosa, or K. pneumoniae species.
- Trial name
- NCT04815798
- Testing
- Bacteriophage-loaded Microcapsule Spray, Standard of Care
- Volunteers
- 69 people
- Sponsor
- Precisio Biotix Therapeutics, Inc.
Bronchiectasis
Research on the Mechanism Affecting Progression of Bronchiectasis
Bronchiectasis is a chronic inflammatory respiratory disease defined as the irreversible dilatation of one or more bronchi and is associated with chronic and frequently purulent expectoration, multiple exacerbations and…
- Trial name
- NCT05731427
- Testing
- Pseudomonas aeruginosa colonization infection, Macrolides
- Where
- 3 sites in China
- Volunteers
- 150 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Bronchiectasis
Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa
It is acknowledged that IL-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response.
- Trial name
- NCT02491723
- Testing
- Azithromycin
- Where
- China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Jin-Fu Xu
Cystic Fibrosis
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P.
- Trial name
- NCT03669614
- Testing
- Inhaled AR-501
- Where
- 25 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Aridis Pharmaceuticals, Inc.
Cystic Fibrosis, Bacterial Infections
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis
OBJECTIVES: I. Assess the efficacy of monthly intravenous mucoid exopolysaccharide Pseudomonas aeruginosa immune globulin (MEP IGIV) given over 1 year in reducing the frequency of acute pulmonary exacerbation in patients with…
- Trial name
- NCT00004747
- Testing
- mucoid exopolysaccharide P. aeruginosa immune globulin IV
- Volunteers
- 170 people
- Sponsor
- National Center for Research Resources (NCRR)
Joint Infection
Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa
This is a single patient study (SPS) that aims to test the bacteriophage treatment as an experimental treatment on a patient suffering from chronic periprosthetic joint infection (PJI) of the right hip.
- Trial name
- NCT06798168
- Testing
- Combining bacteriophage therapy with antibiotics for a case with hip PJI
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Cystic Fibrosis
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
The purpose of this study is to evaluate the long term safety and tolerability of Liposomal Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic infection due to pseudomonas aeruginosa.
- Trial name
- NCT01316276
- Testing
- Liposomal amikacin for inhalation
- Where
- 50 sites in Austria, Belgium and 15 more
- Volunteers
- 206 people
- Sponsor
- Insmed Incorporated
Wound Infection
Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients
The objective of PHAGOBURN is to assess tolerance and efficacy of local bacteriophage treatment of E. coli or P. aeruginosa wound infections in burned patients.
- Trial name
- PHAGOBURN (NCT02116010)
- Testing
- E. coli Phages cocktail, Standard of care : Silver Sulfadiazine, P. Aeruginosa, Phages cocktail
- Where
- 5 sites in Belgium, France and 1 more
- Sponsor
- Phagenix